Diabetic dyslipidemia: a case for aggressive intervention in the absence of clinical trial and cost effectiveness data.

Diabetic dyslipidemia: a case for aggressive intervention in the absence of clinical trial and cost effectiveness data. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Diabetic dyslipidemia: a case for aggressive intervention in the absence of clinical trial and cost effectiveness data. Abstract Text:

G F Lewis,

Patients with diabetes mellitus have a two- to fourfold increase in clinical manifestations of atherosclerotic cardiovascular disease (ASCVD). Traditional risk factors such as age, hypertension, left ventricular hypertrophy, hyperlipidemia and smoking are still operative in diabetes but do not account for the total increase in ASCVD risk associated with diabetes. The most common lipid abnormalities in noninsulin-dependent diabetes mellitus and poorly controlled insulin-dependent diabetes mellitus are hypertriglyceridemia and low high density lipoprotein cholesterol. Evidence is presented to support the hypothesis that these lipid abnormalities are atherogenic in diabetes. Treatment of diabetic dyslipidemia with conservative measures (diet, weight loss, aerobic exercise, improved glycemic control) and pharmacological management have been shown to be highly effective in normalizing the lipid abnormalities. However, few trials of lipid lowering therapy have included patients with known diabetes mellitus and, to date, there have been no well-controlled prospective trials of lipid lowering therapy in diabetes. There is therefore no definitive proof regarding the benefit of lipid lowering therapy in diabetes mellitus. There are also no data regarding the cost effectiveness of lipid lowering therapy in reducing ASCVD complications in diabetes. There are data, however, showing that complications of ASCVD in patients with diabetes account for a large percentage of total health care expenditures. The overwhelming evidence that patients with diabetes have a high rate of ASCVD, that traditional risk factors for ASCVD are operative in diabetes and that the dyslipidemia of diabetes is highly prevalent and proatherogenic, predicts that the treatment of ASVD risk factors, including dyslipidemia, will be associated with a substantial reduction in ASCVD complications.(ABSTRACT TRUNCATED AT 250 WORDS)

Diabetic dyslipidemia: a case for aggressive intervention in the absence of clinical trial and cost effectiveness data. Publishing Authors By Initials

GF Lewis,

For similar behavior and behavior mechanisms: behavior: habits: smoking research abstracts see: behavior and behavior mechanisms: behavior: habits: smoking research

PUBMED ID PMID:

MEDLINE DATE:

Diabetic dyslipidemia: a case for aggressive intervention in the absence of clinical trial and cost effectiveness data. Journal Published:

PUBLICATION TYPE: Review

Journal: The Canadian journal of cardiology

VOLUME: 11 Suppl C

Page Numbers: 24C-28C

Journal Abbreviation:

ISSN: 1916-7075

DAY: 3

MONTH: May

YEAR: 1995

Diabetic dyslipidemia: a case for aggressive intervention in the absence of clinical trial and cost effectiveness data. Information

Number of References: 35

LANGUAGE: eng

NlmUniqueID: 8510280

Diabetic dyslipidemia: a case for aggressive intervention in the absence of clinical trial and cost effectiveness data. Keywords Mesh Terms:

KEYWORDS: Smoking

MESH TERMS: adverse effects

Chemical & Substance for Abstract: Diabetic dyslipidemia: a case for aggressive intervention in the absence of clinical trial and cost effectiveness data. Information

Substance Name: Antilipemic Agents

Registry Number: 0

Grant and Affiliation Information for Diabetic dyslipidemia: a case for aggressive intervention in the absence of clinical trial and cost effectiveness data.

AFFILIATION: Department of Medicine, University of Toronto, Ontario.

Country: CANADA

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Can J Cardiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Diabetic dyslipidemia: a case for aggressive intervention in the absence of clinical trial and cost effectiveness data Related Publications

• 64Cu-azabicyclo[3.2.2]nonane thiosemicarbazone complexes: radiopharmaceuticals for PET of topoisomerase II expression in tumors.
• A state space analysis of emotion and flexibility in parent-child interactions.
• Analysis of the volatile components of cheddar cheese by direct thermal desorption-GC x GC-TOF/MS.
• Brain activation when hearing one's own and others' names.
• Candida albicans biofilms produce antifungal-tolerant persister cells.
• Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.
• Conjugating berberine to a multidrug efflux pump inhibitor creates an effective antimicrobial.
• Contemporary developments in thin-layer chromatography.
• Determinants of plasma HDL concentrations and reverse cholesterol transport.
• Dopamine innervation of the monkey mediodorsal thalamus: Location of projection neurons and ultrastructural characteristics of axon terminals.
• Environmental impacts of dredging on seagrasses: a review.
• Hip Abductor and Knee Extensor Muscle Strength of Children with and without Down Syndrome.
• Hospital disaster preparedness in Los Angeles County.
• Identification and characterization of a cell surface protein of Prevotella intermedia 17 with broad-spectrum binding activity for extracellular matrix proteins.
• Intracellular cGMP may promote Ca2+-dependent and Ca2+-independent release of catecholamines from sympathetic nerve terminals.
• L-beta,beta-dimethylcysteine attenuates the haemodynamic responses elicited by systemic injections of peroxynitrite in anaesthetized rats.
• Metal-organic complexation in the marine environment.
• Multiwire Gas Proportional Counters: Decrepit Antiques or ClassicPerformers?
• Open the door whenever opportunity knocks.
• Production of non-standard PET radionuclides and the application of radiopharmaceuticals labeled with these nuclides.
• Quality of manufacturer provided information on safety and efficacy claims for dietary supplements for colonic health.
• Recent advances in health professional training on substance abuse disorders.
• Regulation of CRAC channel activity by recruitment of silent channels to a high open-probability gating mode.
• Sex-linked congenital deafness.
• Spontaneous uterine infections are associated with elevated prostaglandin F(2)alpha metabolite concentrations in postpartum dairy cows.
• The early alcoholism treatment movement in Australia, 1859-1939.
• The relationship between plasma homocysteine, red cell folate and plasma vitamin B12 in a sample of the New South Wales Central Coast population.
• Transcranial magnetic stimulation: a possible treatment for TBI.
• Two novel human serine/threonine kinases with homologies to the cell cycle regulating Xenopus MO15, and NIMA kinases: cloning and characterization of their expression pattern.
• Uterine involution and postpartum ovarian activity in Nili-Ravi buffaloes.